In the face of an increasingly complex global pandemic and constantly evolving healthcare cost structures, one thing has become abundantly clear for orthopedic surgeons in the United States: total ...
The PREVENA RESTOR™ Therapy portfolio optimizes post-operative care by delivering negative pressure therapy to the incision and surrounding soft tissue to enhance recovery ST. PAUL, Minn.--(BUSINESS ...
ST. PAUL, Minn.--(BUSINESS WIRE)--3M today announced new data demonstrating the PREVENA™ Incision Management System significantly mitigated 90-day surgical site complications (SSCs) and readmission ...
The top concerns for most surgeons today are post-operative complications and infections. Negative pressure therapy promises to help surgeons reduce these risks and their associated costs. During a ...
SAN ANTONIO--(BUSINESS WIRE)--KCI, an Acelity Company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s De Novo request for the PREVENA™ Incision Management ...
In December 2025, Solventum announced updated consensus recommendations from an international panel on the clinical use of closed incision negative pressure therapy (ciNPT) with its proprietary ...
Research presented at the 30th American Association of Hip and Knee Surgeons Annual Meeting (AAHKS) builds on existing evidence that PREVENA™ Therapy lowers surgical site complications and readmission ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results